Literature DB >> 16141002

Collagen VI related muscle disorders.

A K Lampe1, K M D Bushby.   

Abstract

Mutations in the genes encoding collagen VI (COL6A1, COL6A2, and COL6A3) cause Bethlem myopathy (BM) and Ullrich congenital muscular dystrophy (UCMD), two conditions which were previously believed to be completely separate entities. BM is a relatively mild dominantly inherited disorder characterised by proximal weakness and distal joint contractures. UCMD was originally described as an autosomal recessive condition causing severe muscle weakness with proximal joint contractures and distal hyperlaxity. Here we review the clinical phenotypes of BM and UCMD and their diagnosis and management, and provide an overview of the current knowledge of the pathogenesis of collagen VI related disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141002      PMCID: PMC1736127          DOI: 10.1136/jmg.2002.002311

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  130 in total

1.  A new case of Ullrich's disease.

Authors:  L Santoro; C Marmo; P Gasparo-Rippa; A Toscano; F Sadile; F Barbieri
Journal:  Clin Neuropathol       Date:  1989 Mar-Apr       Impact factor: 1.368

2.  Amino acid sequence of the triple-helical domain of human collagen type VI.

Authors:  M L Chu; D Conway; T C Pan; C Baldwin; K Mann; R Deutzmann; R Timpl
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

3.  Head to tail organization of the human COL6A1 and COL6A2 genes by fiber-FISH.

Authors:  M Heiskanen; B Saitta; A Palotie; M L Chu
Journal:  Genomics       Date:  1995-10-10       Impact factor: 5.736

4.  Self-assembly of collagen I from a proband homozygous for a mutation that substituted serine for glycine at position 661 in the alpha 2(I) chain. Possible relationship between the effects of mutations on critical concentration and the severity of the phenotype.

Authors:  A M Romanic; L D Spotila; E Adachi; J Engel; Y Hojima; D J Prockop
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

5.  Immunochemistry, genuine size and tissue localization of collagen VI.

Authors:  H von der Mark; M Aumailley; G Wick; R Fleischmajer; R Timpl
Journal:  Eur J Biochem       Date:  1984-08-01

6.  Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures.

Authors:  Charlotte Wiberg; Dick Heinegård; Christina Wenglén; Rupert Timpl; Matthias Mörgelin
Journal:  J Biol Chem       Date:  2002-09-26       Impact factor: 5.157

7.  Muscle magnetic resonance imaging in patients with congenital muscular dystrophy and Ullrich phenotype.

Authors:  E Mercuri; C Cini; A Pichiecchio; J Allsop; S Counsell; Z Zolkipli; S Messina; M Kinali; S C Brown; C Jimenez; M Brockington; Y Yuva; C A Sewry; F Muntoni
Journal:  Neuromuscul Disord       Date:  2003-09       Impact factor: 4.296

8.  Characterization of the human alpha 1(VI) collagen promoter and its comparison with human alpha 2(VI) promoters.

Authors:  B Saitta; M L Chu
Journal:  Eur J Biochem       Date:  1995-12-01

9.  Long-term noninvasive ventilation in children and adolescents with neuromuscular disorders.

Authors:  U Mellies; R Ragette; C Dohna Schwake; H Boehm; T Voit; H Teschler
Journal:  Eur Respir J       Date:  2003-10       Impact factor: 16.671

10.  Structure of recombinant N-terminal globule of type VI collagen alpha 3 chain and its binding to heparin and hyaluronan.

Authors:  U Specks; U Mayer; R Nischt; T Spissinger; K Mann; R Timpl; J Engel; M L Chu
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  133 in total

1.  Activation of autophagy is required for muscle homeostasis during physical exercise.

Authors:  Usha Nair; Daniel J Klionsky
Journal:  Autophagy       Date:  2011-12       Impact factor: 16.016

2.  Collagen VI microfibril formation is abolished by an {alpha}2(VI) von Willebrand factor type A domain mutation in a patient with Ullrich congenital muscular dystrophy.

Authors:  Leona D Tooley; Laura K Zamurs; Nicola Beecher; Naomi L Baker; Rachel A Peat; Naomi E Adams; John F Bateman; Kathryn N North; Clair Baldock; Shireen R Lamandé
Journal:  J Biol Chem       Date:  2010-08-21       Impact factor: 5.157

Review 3.  Congenital muscular dystrophies: toward molecular therapeutic interventions.

Authors:  James Collins; Carsten G Bönnemann
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

4.  Autophagy thwarts muscle disease.

Authors:  Aviva M Tolkovsky
Journal:  Nat Med       Date:  2010-11       Impact factor: 53.440

5.  Structure of a collagen VI α3 chain VWA domain array: adaptability and functional implications of myopathy causing mutations.

Authors:  Herimela Solomon-Degefa; Jan M Gebauer; Cy M Jeffries; Carolin D Freiburg; Patrick Meckelburg; Louise E Bird; Ulrich Baumann; Dmitri I Svergun; Raymond J Owens; Jörn M Werner; Elmar Behrmann; Mats Paulsson; Raimund Wagener
Journal:  J Biol Chem       Date:  2020-07-21       Impact factor: 5.157

Review 6.  The congenital muscular dystrophies: recent advances and molecular insights.

Authors:  Jerry R Mendell; Daniel R Boué; Paul T Martin
Journal:  Pediatr Dev Pathol       Date:  2006 Nov-Dec

Review 7.  Redox-relevant aspects of the extracellular matrix and its cellular contacts via integrins.

Authors:  Johannes A Eble; Flávia Figueiredo de Rezende
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

8.  Loss of dermatan-4-sulfotransferase 1 function results in adducted thumb-clubfoot syndrome.

Authors:  Munis Dündar; Thomas Müller; Qi Zhang; Jing Pan; Beat Steinmann; Julia Vodopiutz; Robert Gruber; Tohru Sonoda; Birgit Krabichler; Gerd Utermann; Jacques U Baenziger; Lijuan Zhang; Andreas R Janecke
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

Review 9.  Mitochondrial dysfunction and defective autophagy in the pathogenesis of collagen VI muscular dystrophies.

Authors:  Paolo Bernardi; Paolo Bonaldo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

Review 10.  Recent advances using zebrafish animal models for muscle disease drug discovery.

Authors:  Lisa Maves
Journal:  Expert Opin Drug Discov       Date:  2014-06-14       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.